Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Since 2021, there’s been an increase in representation of people from underrepresented and underserved communities in Super ...

In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111 ...

The Super Bowl has always been more than a game—it’s a cultural barometer, reflecting how brands engage with audiences at the ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Banzai International (NASDAQ:BNZI) on Thursday announced the appointment of Nancy Norton as chief legal officer (CLO). Prior to joining Banzai, Norton served as vice president, legal at Novartis.

This article discusses the Anti-Kickback Statute and the False Claims Act. "When coupled with the False Claims Act (FCA), the AKS turns into a potent civil enforcement tool that carries many of the ...